TheManUpstairs
DCAing $IMNN regularly. Just a few more buys left to fill my starter position.
From there, I’d love to see either a non-dilutive ex-US partnership — where I’d resume accumulating — or a new financing that tanks the price, allowing me to deploy heavy dry powder at a deep discount.
Beyond the remarkable efficacy signal and OS benefit, the safety profile looks increasingly de-risked (September IDMC review).
Tons of catalysts ahead — enrollment acceleration, the 80-patient milestone in Q1 2027, a potential non-dilutive ex-US partnership, and eventually the first interim efficacy readout.
oversold $IMNN means
1
3
